• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy and safety of levosimendan and dobutamine in heart failure: A systematic review and meta-analysis.

作者信息

Jaguszewski Milosz J, Gasecka Aleksandra, Targonski Radoslaw, Filipiak Krzysztof J, Szarpak Lukasz

机构信息

1st Department of Cardiology, Medical University of Gdansk, Gdansk, Poland.

First Chair and Department of Cardiology, Medical University of Warsaw, Poland.

出版信息

Cardiol J. 2021;28(3):492-493. doi: 10.5603/CJ.a2021.0037. Epub 2021 Apr 12.

DOI:10.5603/CJ.a2021.0037
PMID:33843036
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8169199/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8219/8169199/dc7698463f21/cardj-28-3-492f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8219/8169199/dc7698463f21/cardj-28-3-492f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8219/8169199/dc7698463f21/cardj-28-3-492f1.jpg

相似文献

1
Efficacy and safety of levosimendan and dobutamine in heart failure: A systematic review and meta-analysis.左西孟旦与多巴酚丁胺治疗心力衰竭的疗效与安全性：一项系统评价和荟萃分析。
Cardiol J. 2021;28(3):492-493. doi: 10.5603/CJ.a2021.0037. Epub 2021 Apr 12.
2
Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.重度低心排血量心力衰竭患者中静脉注射左西孟旦与多巴酚丁胺疗效及安全性比较（LIDO研究）：一项随机双盲试验
Lancet. 2002 Jul 20;360(9328):196-202. doi: 10.1016/s0140-6736(02)09455-2.
3
Levosimendan Treatment for Heart Failure: A Systematic Review and Meta-Analysis.左西孟旦治疗心力衰竭：一项系统评价与荟萃分析
J Cardiothorac Vasc Anesth. 2015 Dec;29(6):1415-25. doi: 10.1053/j.jvca.2015.03.023. Epub 2015 Mar 26.
4
The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.左西孟旦与多巴酚丁胺对比及联合应用于失代偿性心力衰竭治疗的研究
Expert Opin Pharmacother. 2007 Apr;8(5):665-77. doi: 10.1517/14656566.8.5.665.
5
Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.在严重低输出量心力衰竭中，与多巴酚丁胺相比，静脉注射左西孟旦治疗具有成本效益：基于国际LIDO试验的分析。
Eur J Heart Fail. 2003 Jan;5(1):101-8. doi: 10.1016/s1388-9842(02)00246-5.
6
Repetitive use of levosimendan in clinical practice: a case series.重复使用左西孟旦的临床实践：病例系列。
Cardiovasc J Afr. 2021;32(6):339-342. doi: 10.5830/CVJA-2020-058. Epub 2021 Jan 15.
7
[Levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias during 24-hour infusion in patients with acute decompensated heart failure].对于急性失代偿性心力衰竭患者，在24小时输注过程中，左西孟旦和多巴酚丁胺引发心律失常的潜在风险情况相似。
Turk Kardiyol Dern Ars. 2010 Jul;38(5):334-40.
8
Acute effects of levosimendan and dobutamine on QRS duration in patients with heart failure.左西孟旦和多巴酚丁胺对心力衰竭患者 QRS 时限的急性影响。
Arq Bras Cardiol. 2010 Dec;95(6):738-42. doi: 10.1590/s0066-782x2010005000143. Epub 2010 Nov 12.
9
Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).新型钙增敏剂左西孟旦治疗急性心肌梗死所致左心室衰竭患者的安全性和有效性：一项随机、安慰剂对照、双盲研究（RUSSLAN）
Eur Heart J. 2002 Sep;23(18):1422-32. doi: 10.1053/euhj.2001.3158.
10
Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.采用新型组织多普勒衍生指标评估左西孟旦和多巴酚丁胺对晚期心力衰竭患者左心室收缩功能的持续影响。
Cardiol J. 2015;22(1):87-93. doi: 10.5603/CJ.a2014.0044. Epub 2014 May 20.

引用本文的文献

1
Levosimendan and Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials.左西孟旦与心房颤动：一项随机对照试验的荟萃分析。
Arq Bras Cardiol. 2024 Jul;121(7):e20230856. doi: 10.36660/abc.20230856.
2
Effect of levosimendan on ventricular remodelling in patients with left ventricular systolic dysfunction: a meta-analysis.左西孟旦对左心室收缩功能障碍患者心室重构的影响：一项荟萃分析。
ESC Heart Fail. 2024 Jun;11(3):1352-1376. doi: 10.1002/ehf2.14714. Epub 2024 Feb 28.
3
Mortality reduction with levosimendan in patients with heart failure: Current evidence is underpowered.

本文引用的文献

1
Levosimendan in the treatment of patients with acute cardiac conditions: an expert opinion of the Association of Intensive Cardiac Care of the Polish Cardiac Society.左西孟旦治疗急性心脏疾病患者：波兰心脏病学会重症心脏护理协会的专家意见。
Kardiol Pol. 2020 Aug 25;78(7-8):825-834. doi: 10.33963/KP.15551. Epub 2020 Aug 12.
2
Use of levosimendan in acute heart failure.左西孟旦在急性心力衰竭中的应用。
Eur Heart J Suppl. 2018 Dec;20(Suppl I):I2-I10. doi: 10.1093/eurheartj/suy039. Epub 2018 Dec 11.
3
Levosimendan accelerates recovery in patients with takotsubo cardiomyopathy.
左西孟旦降低心力衰竭患者死亡率：当前证据不足。
Cardiol J. 2021;28(5):798-799. doi: 10.5603/CJ.a2021.0078. Epub 2021 Jul 9.
左西孟旦可加速应激性心肌病患者的康复。
Cardiol J. 2016;23(6):610-615. doi: 10.5603/CJ.a2016.0100. Epub 2016 Dec 2.
4
Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.左西孟旦的药理学：变力、血管扩张和心脏保护作用。
J Clin Pharm Ther. 2013 Oct;38(5):341-9. doi: 10.1111/jcpt.12067. Epub 2013 Apr 18.
5
The cardioprotective effects of levosimendan: preclinical and clinical evidence.左西孟旦的心脏保护作用：临床前和临床证据。
J Cardiovasc Pharmacol. 2007 Sep;50(3):257-63. doi: 10.1097/FJC.0b013e3180986230.
6
Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes.急性心力衰竭综合征管理中多巴酚丁胺、多巴胺和米力农的重新评估
Am J Cardiol. 2005 Sep 19;96(6A):47G-58G. doi: 10.1016/j.amjcard.2005.07.021.
7
Estimating the mean and variance from the median, range, and the size of a sample.根据中位数、极差和样本量估计均值和方差。
BMC Med Res Methodol. 2005 Apr 20;5:13. doi: 10.1186/1471-2288-5-13.
8
Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators.左西孟旦对重度心力衰竭患者的急性血流动力学及临床效应。研究人员
Circulation. 2000 Oct 31;102(18):2222-7. doi: 10.1161/01.cir.102.18.2222.